During the treatment of anatrobolic, it was associated with significantly accelerated bone density (BMD) loss.
, researchers included 1,410 post-menopause women in the BMD subgroup, with a baseline T score of three levels based on their spine or collar, according to a recent study published in British Journal of Cancer, an authoritative journal in the field of oncology.
The main purpose of this analysis was to investigate whether BMD measured by the bier energy X-ray absorption assay (DXA) of the spine and hips changed two years after discontinuation of treatment (year 5 to 7).
528 women who were not treated with bisphosphonate received BMD data for five and seven years.
In women with normal BMD at baseline, the researchers observed a 1.25% increase in lumbar BMD after anatrophosopy (95% CI is 0.73-1.77) (P-0.0004), a significant increase over the placebo group (-0.29-0.56).
hips, BMD remained unchanged for 5-7 years in patients taking the anatrophotosis group, while BMD, randomly assigned to the comfort group, continued to decline (-1.35% (-1.70 to -0.98).
, this is the first study to report stopping BMD changes in anatrophospons in breast cancer patients.
the results of this study show that the negative effects of anatroconol on preventing breast cancer on BMD are reversible.